Boehringer Ingelheim has established a research collaboration with the Harvard Stem Cell Institute's – Harvard Fibrosis Network to discover new ways of treating fibrotic diseases such as idiopathic pulmonary fibrosis (IPF), chronic kidney disease (CKD) and nonalcoholic steatohepatitis (NASH). The Harvard Fibrosis Network unites Harvard investigators in several of the university's schools and at Harvard-affiliated Massachusetts General Hospital and Brigham and Women's Hospital.

In collaboration with the Harvard Stem Cell Institute and the Harvard Fibrosis Network, Boehringer Ingelheim is initially sponsoring three projects to explore pathways and molecular targets for the treatment of IPF, CKD, and NASH. Through the research collaboration, the project teams will also have access to the chemical compound collection and siRNA library at the ICCB-Longwood screening facility and will be supported by Shannan Ho Sui's bioinformatics team at the Harvard Chan Bioinformatics Core at the Harvard Stem Cell Institute's Center for Health Bioinformatics to discover new drivers of fibrosis.

All research projects will be sponsored by Boehringer Ingelheim for an initial period of three years with additional projects added upon selection by the joint steering committee. Further details of the agreement were not disclosed.

Source: Boehringer Ingelheim